| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/19/2009 | US7534419 Calibration using chaperone protein |
| 05/19/2009 | US7534240 Negative pressure wound therapy system with provision for introduction of an agent |
| 05/19/2009 | CA2495529C Noonan syndrome gene |
| 05/19/2009 | CA2477260C Site specific delivery of co-administered drugs via inhalation |
| 05/19/2009 | CA2387247C Use of neutralizing agents to growth factors for reducing wound scarring |
| 05/19/2009 | CA2382580C Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| 05/19/2009 | CA2373166C Antiulcer agent |
| 05/19/2009 | CA2367955C Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 05/19/2009 | CA2345724C Use of acylcarnitines as antitumour agents |
| 05/19/2009 | CA2345024C Modified tgf-.beta. superfamily proteins |
| 05/19/2009 | CA2323237C Improved radiation therapy methods |
| 05/19/2009 | CA2318029C Apo-2 ligand |
| 05/19/2009 | CA2312004C Site-specific preparation of polyethylene glycol-grf conjugates |
| 05/19/2009 | CA2247071C Dna vaccination for induction of suppressive t cell response |
| 05/19/2009 | CA2237643C Therapeutic agent for acute hepatic failure |
| 05/19/2009 | CA2211381C Compounds with growth hormone releasing properties |
| 05/19/2009 | CA2206657C Therapeutic preparation for inhalation containing parathyroid hormone, pth |
| 05/19/2009 | CA2163716C Verotoxin pharmaceutical compositions and medical treatments therewith |
| 05/14/2009 | WO2009062143A2 Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
| 05/14/2009 | WO2009062135A1 Hsp90 inhibitors of protein-protein interaction hsp90 chaperone complexes and therapeutic uses thereof |
| 05/14/2009 | WO2009062102A2 Compositions and methods for treatment of microbial disorders |
| 05/14/2009 | WO2009062100A1 Modified recombinant factor viii and von willebrand factor and methods of use |
| 05/14/2009 | WO2009061918A1 Extracellular histones as biomarkers for prognosis and molecular targets for therapy |
| 05/14/2009 | WO2009061894A1 Novel synthesis of beta-nucleosides |
| 05/14/2009 | WO2009061830A1 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| 05/14/2009 | WO2009061807A2 Activin receptor-like kinase-i antagonist compositions and methods of use |
| 05/14/2009 | WO2009061447A2 Use of umbilical cord blood in the treatment of premature birth complications |
| 05/14/2009 | WO2009061395A2 Hcv combination therapies comprising vx-950, peg-ifn and ribavirin |
| 05/14/2009 | WO2009061182A1 Hla class ii pi4k2b mhags and application thereof |
| 05/14/2009 | WO2009061147A1 Compositions and method for the diagnosis, prevention and treament of alzeimer's disease |
| 05/14/2009 | WO2009060915A1 Salivary secretion promoter |
| 05/14/2009 | WO2009060621A1 Medical composition for preventing post-surgical adhesion |
| 05/14/2009 | WO2009060609A1 Method for producing microcapsule using solid fat |
| 05/14/2009 | WO2009060608A1 Sustained release composition containing sdf-1 |
| 05/14/2009 | WO2009060452A2 Methods and compositions for treating biliary cholesterol crystallization and related conditions |
| 05/14/2009 | WO2009060316A2 Hepatitis b virus-binding polypeptides and methods of use thereof |
| 05/14/2009 | WO2009060159A1 Mutated ilt molecules |
| 05/14/2009 | WO2009060112A1 Pharmaceutical composition for cancer treatment |
| 05/14/2009 | WO2009060071A1 Insulin derivative |
| 05/14/2009 | WO2009060013A2 A method for treating ailments of the oral cavity with a krill enzyme composition |
| 05/14/2009 | WO2009059755A2 Novel neurturin conjugates for pharmaceutical use |
| 05/14/2009 | WO2009059450A1 Peptide ligand directed drug delivery |
| 05/14/2009 | WO2009059425A1 Stat3 inhibitors for the treatment of fibrosis |
| 05/14/2009 | WO2009059379A1 Antimicrobial compositions, formulations and uses thereof |
| 05/14/2009 | WO2009042677A3 Stat3 inhibiting compositions and methods |
| 05/14/2009 | WO2009042565A3 Inhibitors of eppin/semenogelin binding as male contraceptives |
| 05/14/2009 | WO2009042162A3 Compositions and methods for inhibiting interleukin pathways |
| 05/14/2009 | WO2009040083A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009040047A3 Therapeutic uses of ghrelin and combinations with stresscopin |
| 05/14/2009 | WO2009040033A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009040019A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009039986A3 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 05/14/2009 | WO2009039854A3 Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| 05/14/2009 | WO2009036997A4 Truncated secretory aspartyl proteinase 2 |
| 05/14/2009 | WO2009036281A3 Bortezomib and process for producing same |
| 05/14/2009 | WO2009033807A3 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 05/14/2009 | WO2009033804A3 Use of gamma- endorphin as a therapeutic agent |
| 05/14/2009 | WO2009033803A3 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 05/14/2009 | WO2009033799A3 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009033754A8 Use of a peptide as a therapeutic agent |
| 05/14/2009 | WO2009021295A3 Inhibition of alpha synuclein toxicity |
| 05/14/2009 | WO2009018429A3 TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 |
| 05/14/2009 | WO2009009396A9 Bri polypeptides and reducing ab aggregation |
| 05/14/2009 | WO2008133759A3 Antiviral peptides |
| 05/14/2009 | WO2008132738A3 Anticancerous polymeric agents |
| 05/14/2009 | WO2008127352A3 Knockout mice for pr01105, pro1279 or pro1783 coding genes |
| 05/14/2009 | WO2008085366A3 Methods and compositions for the killing of cells expressing human cd59 |
| 05/14/2009 | WO2008073884A3 Treating acute renal failure with soluble thrombomodulin variants |
| 05/14/2009 | WO2008064910A9 Metastasis-specific peptides and their diagnostic and therapeutic applications |
| 05/14/2009 | WO2008063092A3 Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics |
| 05/14/2009 | WO2008036835A3 Methods and compositions for upregulation of peroxiredoxin activity |
| 05/14/2009 | WO2007059000A3 Modulation of angiogenesis by a-beta peptide fragments |
| 05/14/2009 | WO2007054977A3 Method and composition for skin depigmentation |
| 05/14/2009 | WO2007038056A3 Protease-resistant forms of vegf-d, method of making and method of use |
| 05/14/2009 | WO2007001399A3 Compositions, splice variants and methods relating to cancer specific genes and proteins |
| 05/14/2009 | WO2006060513A3 Toll like receptor 3 antagonists, methods and uses |
| 05/14/2009 | WO2006050280A3 Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| 05/14/2009 | WO2005113823A3 Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same |
| 05/14/2009 | WO2005113809A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/14/2009 | WO2005079363A3 Aptamer therapeutics useful in the treatment of complement-related disorders |
| 05/14/2009 | US20090124831 Lysine-d-amphetamine dimesylate; sustained release of amphetamine; Oral bioavailability of amphetamine maintained at useful doses, but bioavailability at higher dose substantially reduced; attention deficit disorder; hyperacctivity; narcolepsy; obesity; drug abuse, drug dependency |
| 05/14/2009 | US20090124793 Corticotropin releasing factor 2 receptor agonists |
| 05/14/2009 | US20090124700 Administering L-lysine-d-amphetamine or salts |
| 05/14/2009 | US20090124696 Abuse-resistant amphetamine prodrugs |
| 05/14/2009 | US20090124627 Compositions for sleeping disorders |
| 05/14/2009 | US20090124592 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity |
| 05/14/2009 | US20090124568 Use of stem cells to generate inner ear cells |
| 05/14/2009 | US20090124567 Influenza Therapeutic |
| 05/14/2009 | US20090124560 Composition Containing Peptide as Active Ingredient |
| 05/14/2009 | US20090124559 Soft Protease Inhibitors and Pro-Soft Forms Thereof |
| 05/14/2009 | US20090124558 Compositions and methods for treating neural anoxia and spreading depression |
| 05/14/2009 | US20090124557 Compositions and methods for treating cancer |
| 05/14/2009 | US20090124556 Peptides Exhibiting Efficacies of Improvement in Skin Conditions or Treatment of Periodental Diseases |
| 05/14/2009 | US20090124555 Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents |
| 05/14/2009 | US20090124554 Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| 05/14/2009 | US20090124553 Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor |
| 05/14/2009 | US20090124552 Methods and Compositions for Regenerating Connective Tissue |
| 05/14/2009 | US20090124551 Methods of administering bone health compositions derived from milk |
| 05/14/2009 | US20090124550 Thrombin peptide derivative dimers |
| 05/14/2009 | US20090124549 administering to a patient infected with mycobacterium tuberculosis, a therapeutically effective amount of an isolated polypeptide ( a polypeptide covalently linked to a carrier); protective immune response |